CDA | Evidence Driven
CDA | Evidence Driven

Lartruvo for Advanced Soft Tissue Sarcoma – Details

Details

Files
Generic Name:
Olaratumab
Project Status:
Complete
Therapeutic Area:
Advanced Soft Tissue Sarcoma
Manufacturer:
Eli Lilly Canada Inc.
Brand Name:
Lartruvo
Project Line:
Reimbursement Review
Project Number:
PC0111-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
10 mg/mL
Tumour Type:
Sarcoma
Indications:
Advanced Soft Tissue Sarcoma (STS)
Funding Request:
In combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and for whom treatment with an anthracycline-containing regimen is appropriate
Pre Noc Submission:
Yes
Sponsor:
Eli Lilly Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Olaratumab (Lartruvo) STS – pERC Final Recommendation Final Recommendation April 18, 2018 View PDF
Olaratumab (Lartruvo) Advanced Soft Tissue Sarcoma – Final Clinical Guidance Report Guidance Reports April 18, 2018 View PDF
Olaratumab (Lartruvo) Advanced Soft Tissue Sarcoma – Final Economic Guidance Report Guidance Reports April 18, 2018 View PDF
Olaratumab (Lartruvo) Advanced Soft Tissue Sarcoma – pERC Initial Recommendation Initial Recommendation March 29, 2018 View PDF
Olaratumab (Lartruvo) STS – PAG Feedback on Initial Recommendation Feedback April 18, 2018 View PDF
Olaratumab (Lartruvo) STS – Manufacturer Feedback on Initial Recommendation Feedback April 18, 2018 View PDF
Olaratumab (Lartruvo) STS – Clinician Feedback on Initial Recommendation Feedback April 18, 2018 View PDF
Olaratumab (Lartruvo) STS – Patient Group COI Declarations COI Declarations April 18, 2018 View PDF
Olaratumab (Lartruvo) STS – Clinician COI Declarations COI Declarations April 18, 2018 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : May 3, 2018